The most specific finding is tender or thickened temporal arteries with decreased ... or rarely over the orbits. Giant cell arteritis is a systemic vasculitis and careful attention should be ...

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the ...

has approved Rinvoq for the treatment of adults with giant cell arteritis (GCA). GCA is an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta ...

The FDA has approved the Janus kinase inhibitor upadacitinib for the treatment of giant cell arteritis in adults, the first such approval in the disease since tocilizumab received the green light in ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 SELECT-GCA trial.

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib), 15 mg, once daily, for the treatment of adults with giant ...

for the treatment of adults with giant cell arteritis (GCA). 1 This comes after the European Commission recently granted marketing authorization of RINVOQ for the treatment of GCA in adult patients.

AbbVie has picked up another indication for its JAK inhibitor Rinvoq in the EU, becoming the first approved oral therapy for giant cell arteritis (GCA), an autoimmune disease affecting the arteries.

The US Food and Drug Administration (FDA) has granted approval for AbbVie’s 15mg Rinvoq (upadacitinib) to treat adults with giant cell arteritis (GCA). The approval follows the recent marketing ...